Locus Biosciences, Inc.

Extensive studies by the HUN-REN Biological Research Centre in Szeged, Hungary, have demonstrated that even newly developed antibiotics can quickly provoke resistance in pathogens due to the rapid adaptation of pre-existing mutations in bacterial populations. This resistance likely arises from conserved mechanisms shared with older antibiotics, underscoring the need for new approaches to antibiotic development.   At Locus, we adapt at the speed of biology. Our platform is built to combat resistance by engineering naturally occurring bacterial viruses and building cocktails that complement each other to achieve optimal killing potential. Should resistance occur, our products are adaptable, which means we don't need to go all the way back to the starting line. Instead of developing drugs kept safeguarded for fear of resistance or therapies tailored to an individual, we are creating scalable, precision therapies designed to treat everyone.   #precisionmedicine #LOCUSAI #adapt 

Nick Conley, Ph.D., recently presented at the 21st BayHelix Annual Conference. Thank you to BayHelix for hosting this event! Our CTO shared insights into the LOCUS #AI platform and discussed new, groundbreaking therapies in the field as a panelist alongside other industry leaders.

We are thrilled to work with the strong Life Sciences Group at BridgeBank. Together, we will tackle #AMR and change the face of precision medicine.

Locus Biosciences is thrilled to receive a $10,000,000 tranched term loan from Bridge Bank to help us achieve our growth objectives. Big thank-you to Bill Wickline, Lan Zhu, and Phil Ho in the Lifesciences Group. Locus Biosciences is a cutting-edge #precisionmedicine company leveraging artificial intelligence to develop engineered bacteriophage therapeutics. Our innovative treatments precisely target and eliminate harmful bacteria while preserving the rest of the microbiome. We are applying our groundbreaking #LOCUSAI platform to address infectious diseases and immunological conditions, including pioneering a novel therapy for Crohn’s disease. #innovation #fundraising #investment

Did you know that more than 3 million people in the US suffer from inflammatory bowel disease? IBD is a debilitating disease causing severe abdominal pain that is frequently stigmatized. With the beginning of Crohn's & Colitis Awareness Week, we can spark awareness and foster support for those impacted.   At Locus, we are committed to developing better treatments that improve quality of life for those fighting IBD. #CCAwarenessWeek

As we reflect on the global progress highlighted during AMR Awareness Week, we are grateful for the support of CARB-X and Biomedical Advanced Research and Development Authority (BARDA) in tackling this pressing issue. These partnerships enable us to continue optimizing our treatments and provide us with the opportunity to manufacture everything in-house.   The #ELIMINATE trial focuses on recurrent infections caused by drug-resistant E. coli. Our goal is to improve patients' quality of life and offer an alternative treatment option where traditional antibiotics fail. To learn more about the trial, visit: https://lnkd.in/gs4QGYgj.

At Locus, we have industrialized the process of building engineered phage therapies. With the help of the Locus #AI platform, we believe we can target any bacterial pathogen and create a precision drug to address that threat. #WAAW #precisionmedicine

Superbugs, or antibiotic-resistant bacteria, are evolving to withstand the very medicines designed to eliminate them, making infections increasingly difficult—and sometimes impossible—to treat. Antibiotics often lack specificity, leading to off-target effects that disrupt the microbiome and destroy beneficial bacteria. Meanwhile, pathogenic bacteria that survive treatment grow increasingly resistant over time. In contrast, our engineered phages are highly specific, targeting only harmful bacteria while preserving the rest of the microbiome. Phages recognize unique receptors on their target pathogens and bind to them, exploiting the significant differences between these pathogens and beneficial bacteria. A precision approach is a stewardship approach. #LOCUSAI #precisionmedicine #WAAW

On Day 2 of #WorldAMRAwarenessWeek, we want to shine a light on a long-sought-after solution to AMR: #phagetherapy. But what is a phage?   Phages are viruses that target only bacteria, and they are everywhere! They are the most abundant organism on Earth, vastly outnumbering all other organisms including bacteria. They are ubiquitous in the environment, found in the food we eat and water we drink, and play a crucial role in regulating bacterial populations.   Phages are nature's precision tool against bacteria. At Locus, we tip the ecological balance of these natural bacteria killers to fight #antimicrobialresistance. In the fight against AMR, a precision approach is a stewardship approach. To learn more, visit https://www.locus-bio.com/.   #WAAW

Today marks the start of #WorldAMRAwarenessWeek.   #Antimicrobialresistance occurs when microbes develop mechanisms to prevent drugs from working. These drugs make up the bedrock of modern human healthcare and are directly responsible for enabling life-saving surgeries and treatments that have advanced human life expectancy dramatically over the past century.   While these drugs have played a critical role in modern medicine, their diminishing effectiveness underscores the urgent need for innovative therapies to combat resistant infections and safeguard global health. See how Locus is combating AMR with our precision therapies here: https://www.locus-bio.com/.   #AMR #WAAW #precisionmedicine